Active Lung Cancer Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

Why Consider a Lung Cancer Clinical Trial?

• Find Trials That Fit — Browse recruiting Lung Cancer trials pulled directly from ClinicalTrials.gov — updated continuously so you always see real, active studies.
• No Medical Jargon — Eligibility criteria are rewritten into plain yes-or-no questions. It's always okay to answer "not sure" — your doctor can help fill in the rest.
• See How Well You Match — Get a clear picture of how closely a trial fits your situation, so you know which ones are worth bringing to your oncologist.
• Ready for Your Appointment — Generate a printable or emailable summary for your next visit. A caregiver can send it to your doctor ahead of time.

How It Works

1. Share a Few Details — Enter your Lung Cancer type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Lung Cancer Clinical Trial FAQ

Can I join a lung cancer clinical trial if I have brain metastases?

Many lung cancer trials do enroll patients with stable brain metastases, especially immunotherapy and targeted therapy studies. The key eligibility question is usually whether the brain metastases are "stable" — meaning they have not grown recently and you have finished any brain-directed treatment. Always confirm with the trial coordinator, because some trials exclude active brain metastases while others accept them.

Do I need to have tried chemotherapy before joining a lung cancer trial?

It depends on the trial. First-line trials enroll patients who have never received treatment for lung cancer. Second-line and later trials enroll patients whose cancer progressed on prior therapy. Trialify shows you trials from all lines of treatment, and you can filter by stage or disease setting to match your current situation.

Are there lung cancer trials specifically for non-smokers?

Yes. Lung cancer in non-smokers often has distinct molecular drivers — such as EGFR mutations or ALK rearrangements — and many targeted therapy trials specifically seek patients with these alterations. Biomarker testing (a biopsy or liquid biopsy) is usually required before joining these trials, so ask your oncologist about molecular profiling if you haven't had it yet.

What is the difference between NSCLC and SCLC clinical trials?

Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are biologically different diseases with separate trial landscapes. NSCLC trials frequently test targeted agents (for EGFR, ALK, ROS1, KRAS, MET, etc.) and checkpoint immunotherapies. SCLC trials often explore combination immunotherapy, antibody-drug conjugates, and novel agents. When you search on Trialify, selecting your specific histology will filter results to the most relevant studies.

How do I talk to my oncologist about a lung cancer clinical trial I found?

Bring the trial's NCT number (e.g., NCT04567890) and a short summary to your appointment. Trialify generates a printable summary that includes the trial name, NCT ID, phase, key eligibility questions you already answered, and your match assessment — so your doctor can quickly evaluate whether it fits your situation. You can also ask your care team to contact the trial site on your behalf.

Explore Other Cancer Trial Guides

• Non-Small Cell Lung Cancer (NSCLC) — Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, representing about 85% of all cases. Trials are testing EGFR, ALK, KRAS, MET, and RET targeted therapies alongside checkpoint immunotherapy for all stages of NSCLC.
• Small Cell Lung Cancer (SCLC) — Small cell lung cancer (SCLC) is a fast-growing form of lung cancer that accounts for roughly 15% of lung cancer cases. New trials are testing immunotherapy combinations, antibody-drug conjugates (DLL3-targeting agents), and novel mechanisms for both limited- and extensive-stage disease.
• KRAS-Mutated Lung Cancer — KRAS mutations are the most common oncogenic driver in NSCLC, found in approximately 25–30% of adenocarcinomas. Sotorasib and adagrasib are approved for KRAS G12C, and next-generation KRAS inhibitors targeting G12D, G12V, and pan-KRAS are in active clinical trials.
• Bladder Cancer — Bladder cancer trials are evaluating checkpoint immunotherapy, enfortumab vedotin-based combinations, and FGFR inhibitors for both non-muscle-invasive and muscle-invasive disease.